A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.
Publication|Articles|June 19, 2026
Pharmacy Practice in Focus: Oncology
- June 2026
- Volume 8
- Issue 4
Evaluating Clinical Safety of BTK Inhibitors: Cardiovascular Events and Drug-Drug Interactions
Fact checked by: Kirsty Mackay
This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.
Advertisement
Advertisement
Bruton tyrosine kinase inhibitors (BTKis) are standard therapies for B-cell malignancies, including relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This study focuses on CLL/SLL. Although second-generation BTKis offer increased selectivity, their cardiovascular (CV) safety and potential drug-drug interactions (DDIs) remain incompletely characterized. This study describes CV toxicity and cytochrome P450 3A4 (CYP3A4)–mediated interactions of covalent (cBTKi) and noncovalent BTKi (ncBTKi) to inform safer therapy selection.
Related to this article
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
This update came with no changes to the safety sections of labeling, with no new signals identified with longer follow-up.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
A biologic stewardship framework can enhance consistency, safety, and sustainability of biologic use in health systems.
The update shortens required observation to 6 to 8 hours from 22 to 24, easing tarlatamab administration in community settings for ES-SCLC.
Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.
Advertisement
Advertisement